{"filings":[{"id":442476,"accession_number":"0001708599-26-000036","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-05-14T20:05:05+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.","R&D expenses $3.2M, G&A $3.1M; total operating expenses $6.3M.","Cash and equivalents $24.5M at March 31, 2026; additional $5.2M from PIPE in April.","SER-252 Phase 1b registrational study underway; first patient dosed Feb 2026; TFL data from SAD arm expected H1 2027.","Closed $21.2M private placement in March/April 2026; Senior Convertible Note amended to remove further borrowing obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94876,"accession_number":"0001708599-26-000027","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Serina appoints CTO, raises CEO salary to $500K, amends bylaws for Co-Chairs","event_type":"leadership","confidence":"high","bullets":["Srini Tenjarla, Ph.D., promoted to CTO of Serina (AL) subsidiary; salary increased to $425,000 retroactive to Mar 15, 2026.","CEO Steve Ledger salary raised to $500,000 retroactive to Sept 9, 2024; retro payment made in lump sum Apr 2026.","Bylaws amended to allow one or more Co-Chairs with equal authority to call special meetings and preside."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107560,"accession_number":"0001708599-26-000018","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics reports FY2025 net loss of $19.4M; SER-252 Phase 1b initiated; up to $30M financing closed","event_type":"earnings","confidence":"high","bullets":["Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.","FDA IND cleared for SER-252 (advanced Parkinson's); first patient dosed in Phase 1b trial in February 2026.","Private placement of up to $30M closed; $16M received as of March 23, 2026; Greg Bailey appointed Co-Chairman.","ATM program raised $12.9M from 3.5M shares at avg $3.72; additional $10M raised in 2026.","Cash and cash equivalents $3.1M as of December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107559,"accession_number":"0001708599-26-000010","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman","event_type":"other_material","confidence":"high","bullets":["First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.","Pricing at $2.25 per share (68% premium to March 17 close); 50% warrant coverage at $5 exercise (273% premium).","Warrants if fully exercised could add up to $33.3M; total potential funds ~$63.3M to extend runway into 2H 2027.","Proceeds to fund SER-252 registrational trial for advanced Parkinson's; first patient dosed in SAD study.","Greg Bailey, M.D., lead investor, appointed Co-Chairman of Board; existing convertible note amended to eliminate further borrowing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107558,"accession_number":"0001708599-26-000005","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.","Phase 1b registrational study to start; site and regulatory activities in Australia underway.","FDA alignment on 505(b)(2) NDA pathway provides clear development path for SER-252.","CEO Steve Ledger calls milestone a major step toward addressing significant unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107557,"accession_number":"0001708599-26-000003","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Serina Therapeutics receives NYSE American deficiency notice for stockholders' equity below $2M","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $1.6M as of Sept 30, 2025, below $2M, $4M, and $6M thresholds.","Company has until Feb 8, 2026 to submit a plan to regain compliance by July 9, 2027.","Non-compliance triggers NYSE American Section 1009; delisting proceedings may start if plan rejected.","Company intends to submit a plan but cannot assure compliance during the 18-month cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123921,"accession_number":"0001708599-25-000138","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Serina submits complete response to FDA clinical hold for SER-252 Parkinson's program","event_type":"regulatory","confidence":"high","bullets":["Complete response submitted Dec 9, 2025, addressing FDA's clinical hold on SER-252 related to trehalose excipient.","Submission includes detailed data package on trehalose as subcutaneous excipient and revised protocol for SAD phase.","FDA clinical hold does not involve apomorphine drug substance, mechanism of action, enFuse device, or 505(b)(2) pathway.","Global site start-up continues; first-patient-in for Phase 1b registrational study targeted for Q1 2026, subject to hold resolution.","Company acknowledges FDA's engagement and expects SAD phase initiation in Q1 2026 pending regulatory and ethics approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123920,"accession_number":"0001708599-25-000135","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.","FDA placed IND for SER-252 on clinical hold due to excipient question; not related to active drug.","Secured up to $20M convertible note/warrant financing; first $5M drawn in September 2025.","ATM program raised $2.8M net; 474,712 shares issued at avg $6.00 per share.","Cash $8.6M as of Sept 30; R&D expenses rose to $3.6M from $2.4M year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":130000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123919,"accession_number":"0001708599-25-000130","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Serina Therapeutics stockholders elect directors and ratify auditors at 2025 annual meeting","event_type":"other_material","confidence":"high","bullets":["Steve Ledger and Karen J. Wilson elected as directors with over 4.1M votes For each.","Ratification of Frazier & Deeter as independent auditor approved: 6.54M For, 378K Against.","Approval of convertible note and warrants issuance passed: 4.15M For, 108K Against.","Broker non-votes of 2.68M present on director election and note/warrants proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123918,"accession_number":"0001708599-25-000126","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Serina Therapeutics announces FDA clinical hold on SER-252 IND for advanced Parkinson's disease","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on SER-252 IND, requesting additional info on a commonly used excipient; not related to active drug or mechanism.","Serina expects formal clinical-hold letter within 30 days and will work expeditiously with FDA to address requests.","FDA previously indicated support for SER-252 development under 505(b)(2) NDA pathway; CEO remains confident in program.","SER-252 is Serina's lead program for advanced Parkinson's; Phase 1b trial designed as randomized, double-blind, placebo-controlled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123917,"accession_number":"0001708599-25-000122","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Serina Therapeutics draws first $5M tranche from $20M note for SER-252 Parkinson's trial","event_type":"other_material","confidence":"high","bullets":["Received $5 million initial tranche under up to $20 million convertible note financing agreement.","Proceeds to fund registrational Phase 1b trial of SER-252 for advanced Parkinson's disease.","IND submitted to FDA and HREC approval received in Australia; global trial initiation in Q4 2025.","Phase 1b trial design: randomized, double-blind, placebo-controlled with SAD (n=40) and MAD (n=48) cohorts.","Subsequent tranches tied to development milestones including patient enrollment in the clinical trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140592,"accession_number":"0001708599-25-000110","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b","event_type":"debt","confidence":"high","bullets":["Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.","10% annual interest; conversion at $5.18/share; warrants at $5.44/share for 100% of conversion shares.","Lender is Dr. Gregory H. Bailey, board member and affiliate of largest shareholder Juvenescence; approved by independent special committee.","Senior unsecured; prepayable at any time without penalty; mandatory repayment on change of control or liquidity event.","Maturity 5 years from initial funding; customary events of default with 2% default interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140591,"accession_number":"0001708599-25-000108","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial","event_type":"debt","confidence":"high","bullets":["Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.","Convertible at $5.18/share (9/8 close), 10% annual interest payable quarterly after first year, 5-yr maturity.","Each tranche carries 100% warrant coverage at $5.44/share; warrants expire 60 days after first Cohort 2 dose or Sept 30, 2026.","Proceeds to advance SER-252 Phase 1b registrational trial for advanced Parkinson's under 505(b)(2) NDA path.","IND submission planned Q4 2025; dosing in Australia Q4 2025 and U.S. initiation Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140590,"accession_number":"0001708599-25-000105","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA feedback supports registrational trial for SER-252 in advanced Parkinson's under 505(b)(2) NDA pathway","event_type":"other_material","confidence":"high","bullets":["FDA Type B meeting written feedback supports advancing SER-252 (POZ-apomorphine) in registrational study.","Plans to submit U.S. IND in Q4 2025; patient dosing in Australia expected to start in Q4 2025.","U.S. enrollment expected to begin in Q1 2026 after IND clearance.","SER-252-1b study is randomized, double-blind, placebo-controlled Phase 1b with up to 88 patients.","CEO highlights capital-efficient 505(b)(2) pathway; platform may apply to other POZ-enabled small molecules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140589,"accession_number":"0001708599-25-000101","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Serina Therapeutics amends bylaws to add safe harbor procedures and expand forum selection clause","event_type":"other_material","confidence":"high","bullets":["Board adopted Bylaws Amendment on August 18, 2025, effective immediately.","Adds safe harbor procedures for transactions involving interested directors, officers, or control groups.","Expands forum selection clause to cover stockholder claims related to corporate business or governance.","Amendment supplements Section 9.2 of the Amended and Restated Certificate of Incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140588,"accession_number":"0001708599-25-000091","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year","event_type":"earnings","confidence":"high","bullets":["Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).","Revenue $130k (NIH grants) vs $51k YoY; R&D spend up 100% to $3.2M.","Cash $6.0M; projects funding into Q4 2025; raised $1.2M net via ATM at avg $5.95.","Lead candidate SER-252 (POZ-apomorphine) on track for Phase 1 in Q4 2025.","Advanced SER-270 (once-weekly injectable) for tardive dyskinesia; appointed Dr. Brannan to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":130000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140587,"accession_number":"0001708599-25-000076","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina advances SER-270 (POZ-VMAT2i) once-weekly injectable into TD development","event_type":"other_material","confidence":"high","bullets":["SER-270 is a long-acting, once-weekly subcutaneous VMAT2 inhibitor for tardive dyskinesia (TD).","U.S. TD market reached $3.7B in 2024; projected to grow to $5.4B by 2030.","Fewer than 30% of U.S. TD patients are diagnosed; less than half receive treatment.","Serina plans to explore POZ-VMAT2i for Huntington's chorea as a secondary indication.","CEO Steve Ledger to present at BTIG Virtual Biotechnology Conference on July 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140586,"accession_number":"0001708599-25-000065","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.08","8.01","7.01","9.01"],"status":"ready","headline":"Serina Therapeutics sets 2025 annual meeting for Nov 7; updates proposal deadlines","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for November 7, 2025; location and time in proxy.","Rule 14a-8 stockholder proposals must be received by August 15, 2025.","Director nominations and other proposals due August 9, 2025; earliest July 10.","Meeting date change of >30 days from 2024 anniversary triggers adjusted deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158297,"accession_number":"0001708599-25-000058","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"Serina appoints ex-Karuna CMO Brannan to board; director Gross departs","event_type":"leadership","confidence":"high","bullets":["Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.","Brannan led clinical strategy for KarXT, first new schizophrenia mechanism in >30 years, key to Karuna's $14B BMS acquisition.","Remy Gross departed board effective May 22, 2025; no disagreement, stays as consultant.","Filed certificate of correction to Series A Preferred Stock to add conversion price adjustment reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}